is...retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To me this is discouraging info. I am asking "what is wrong with either our drugs or the clinical trials they are in" since we don't have ONE offer. I just read a post that said shareholders need to be told.
I wish I knew how to give him more trouble. People with mouth sores, children with missing eyeballs and women dropping dead from a diseased uterus leaving behind young children are worth a low price. I don't think Leo is getting low prices. Why would he when companies are getting high bids for inferior products. I think Leo is in over his head. He thinks he can be the next Soros. Well let him sell shoes or something to africans or winter coats to ecuadoreans,. He doesn't belong in a humanitarian business IN MY OPINION>
had to laugh out loud after I read your post. Did Leo really say squeeze that trigger"? Who says Leo doesn't read this board LOL LOL.
See what happens when a person takes the trouble to aggravate Leo
Qujit kissing his potootie and insist he stay on the ball.
it's about time.
If he has no data (I believe he has some - B-OM and B-UP) and if they don't show very good results then drag out the CEO salary for as long as possible and wallpaper his bathroom with those results.
I don't think Leo will make a deal. I believe he will always think he could do better. He won't pull the trigger. He likes the game. Sick people aren't on his horizon. imo We shareholders don't have a strong board and Menon now is weakened since Aruda deal. Now Menon and Aruda might unite. That would change the dynamic. I hope so and soon. Send Leo off on his yacht.
don't worry folks think of all those CDA's from big pharma interested in investing in our products. or so some would have us believe. this reminds me of those ASCOs that we were suppose to star at.
sure hope so
The SP is not signaling good results from B OM trial or any other. By now they have an idea. I imagine they are writing a weasel worded PR right now.
If daubers knows I am wrong please post.
Thanks daubersUP. I'll take that to the bank
todays PR
..........separately building on PROMISING RESULTS seen to date
--------------------------------------------------------------------------------------------------------sign a deal already
who is responsible?
maybe it is something you ate
I really dislike that word soon.
For a very rough idea of the outcome all they have to do is count the results.
1) never had sores (there has always been a few patients never got them with no prevention methods.
2) had mild or moderate sores
3) full blown sores
4) different durations of those who got sores.
Hence Menon has a good idea how this went down. imo
tsk tsk lol
daubs you are missing my point. what is 10's of millions if your kid or grandkid is going to loose both eyeballs as a toddler or your loved one is in a hospital with a fatal infection they got since the entered for another treatment or a five year old has mouth tongue and throat ulcers.
Leo does not have the money to run multiple trials hence no phase 3 for B.
Another thing does it look like to you the investment community trusts him ? Why didn't the stock soar on todays or any other news day?
I only hope somebody beats us to market and actually helps people.
I hope you are correct but after being in this stock since arch 2011 i do not have much faith in Leo.
I just don't think he will make a "timely" deal. I think he holds back the not so great news i.e. that K was not being effective at the same pace of the increase in dosage after cohort 4 or 5.
Why can't he make a deal (and by the way help people who suffer greatly and need help) with what he has instead of waiting to make a pill. That colon problem is horrendous. I wouldn't want to wait for a pill. How about BOM and also retinoblastoma. He thinks too much like a guy selling can openers than someone dealing in medicine, I will say he's good at platitudes.
imo
what did that guy in the movie say? I think it was "show me the money". I say its time. going from many to numerous means what exactly? imo nothing if it doesn't lead to an immediate deal.
quote
Moreover, we remain optimistic that one day we will help address, in a substantial way, this area of considerable unmet medical need.”
dontcha love the wording "ONE DAY" like in one day my prince will come don't know why don't know when.
I liked it better when Leo used to say SOON. It was just as vague but seemed more certain to me.
well keep betting on those CDAs.
I keep reading that "we know the company has several CDAs. I don't agree with that statement . We know that the company SAYS they have several CDAs. We don't know any particulars - name of company and what is stipulated. Those things can make a big difference imo
Sometimes i think the results are embellished such as when we were told about p53 activity in cohort 4 etc and at the ASCO demonstrations. Mgmt did not tell us until forced to that the P53 activity did not keep up with the dosage, That makes me skeptical about recent info. My skepticism
is reinforced when i hear CDAs (which we have been reported since before the DF trial) etc. and no names. With this supposed great info the SP should be much higher imo.
Lately we have heard about a short trial for OC i from Dr B. This was going to be TERRIFIC and of short duration. You tell me how you would describe what really happened.
IMO it is time to quit shucking and a jivin and give us the straight scoop.
no kidding, how much time how many CDA's and with whom? i would like to know so i can tell those looking to invest but conspicuously standing n the sidelines.
The FDA granted Gleevec a priority review and approved the drug after only a 2 ½-month review time, making this the fastest approval to market any cancer treatment.
Clinical Data
The FDA approval of Gleevec was based on data from three phase II open-label, single-arm studies that showed a major cytogenetic response (complete response = 0% Philadelphia chromosome-positive [Ph+] metaphases; partial response = up to 35% Ph+ metaphases) in patients with advanced stages of CML. Patients with chronic-phase CML after failure with interferon therapy achieved an 88% hematologic response and 49% overall major cytogenetic response—both primary end points of the study.
Toxicity
The majority of Gleevec-treated patients experienced adverse events at some time. Most events were mild to moderate grade, but the drug was discontinued for adverse events in 1% of patients in chronic phase, 2% in accelerated phase, and 5% in blast crisis. In clinical trials in the three phases of CML studied, adverse events, regardless of relationship to study drug, include nausea (55% to 68%), fluid retention (52% to 68%), muscle cramps (25% to 46%), diarrhea (33% to 49%), vomiting (28% to 54%), hemorrhage (13% to 48%), musculoskeletal pain (27% to 39%), skin rash (32% to 39%), headache, (24% to 28%) and fatigue (24% to 33%). Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe edema was 1% to 5%. More serious side effects include elevated liver enzymes (1.1% to 3.5%), severe superficial edema (1% to 5%), and hemorrhages (0.4% to 16%).
Women of childbearing potential should be advised to avoid becoming pregnant while taking Gleevec. Treatment with Gleevec is often associated with neutropenia and/or thrombocytopenia.
Patient Assistance
Novartis has put a comprehensive patient assistance program in place, which insures that uninsured, indigent patients are not denied therapy for economic reasons. A reimbursement hotline is in place and can be reached at 1-877-GLEEVEC.
RELATED ARTICLES
Gaps Found in Monitoring of Response to TKI Therapy in CML
CML Treatment During Pregnancy Could Increase Risk of Congenital Malformation
Using Patient Variables in CML to Guide Treatment
CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Resource Topics Partner Content
Breast Cancer
Lung Cancer
Bladder Cancer
Colorectal Cancer
Head & Neck Cancer
CURRENT ISSUE
Oncology Vol 31 No 10
Oct 15, 2017 Vol 31 No 10
SUBSCRIBE
Connect with Us
TwitterFacebookLinkedInRSS
I'll try to cut and paste. it is harder for me to do now.
I find it confusing to read posts condemning those who either by design or ignorance help lower the SP by buying the "cheap" shares.
I also am hoping that someone with the ability to do so contacts r Wonderful and tell him the stock price is sinking. I am supposing he doesn't know or he would take steps to defend the SP.
Didn't he say the SP would take care of itself? What in the world did he mean by that?
not to worry. someone must have thought his wonderfulness was worth 400K a year. look for that needle in the haystack.
i would sue.
well ion that case i consider the trial inhumane. all imo
imo we should have had an update on this. just more finagling.
never mind
why? why not the original 36 participants?
maybe it wasn't breakthrough. maybe it was called something else bu it was supposed to happen at 36 participants. if the results were excellent at 36 out of 60 participants the trial would be halted and the drug given approval right then and there because the conditions of the patients were so terrible and no relief at this time is known except for ice chips etc.
Whatever happened to breakthrough designation at 36 patients if results were good? Another "would" "should" turns to oops.
IMO investors just don't believe big pharma is chomping at the bit for IPIX so called miracle drugs.
I think the share price action this morning positively proves big pharma is chomping at the bit to do business with current management.
somehow i have been dropped from the company email list. probably an error.